XDx to go public in $86m flotation:
This article was originally published in Clinica
Molecular diagnostics specialist XDx is aiming to fund clinical trials of its lung transplant rejection test by raising up to $86.25m through an IPO. The Brisbane, California-based company is using patient specimens from a lung allograft rejection study it conducted to test the clinical validity of its AlloMap LTx test. XDx focuses on producing non-invasive gene expression-based tests for monitoring transplant rejection and autoimmune diseases, and already markets its AlloMap HTx test for monitoring gene expression in processed blood samples of patients who have received heart transplants. Proceeds from the IPO will also go towards expanding commercialisation of AlloMap HTx. The company will float on the Nasdaq Stock Exchange under the symbol -XDXI".